Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. H. Kaspar Binz is CEO and founder of Binz Biotech Consulting GmbH, a strategic life-science management consultancy. He is also co-founder of Molecular Partners (SIX: MOLN), a Swiss clinical stage biotech company developing DARPin® drugs for therapeutic applications, where he acted in various positions from 2004 to 2019 including VP and CSO. With his entrepreneurial approach Dr. Binz was key in the establishment of Molecular Partners as a successful biotech company, and in the establishment of Molecular Partners’ Pipeline. He invented and developed the designed repeat protein technology including the DARPin® technology during his post-doctoral training and PhD studies with Prof. Andreas Plückthun at the University of Zürich, Switzerland. Dr. Binz has published widely in the areas of protein engineering and drug development and is inventor on numerous patents and patent applications. Molecular Partners and the DARPin® technology have been awarded with several prizes including the Swiss Technology Award 2005, the Swiss Venture 2004 business plan competition award, and the De Vigier Foundation award 2005. Dr. Binz was educated at the Royal Institute of Technology in Stockholm, Sweden (Prof. Mathias Uhlén) and holds a M.Sc. in biotechnology from the European school of biotechnology in Strasbourg, France.